15 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $1.9B | $165M | 0.0% | 10.9% | — | — | $375M |
| 2024 | $2.0B | -$99M | 0.0% | -3.4% | — | $611M | $230M |
| 2023 | $2.0B | -$60M | 0.0% | 0.4% | — | $622M | $73M |
| 2022 | $2.0B | $66M | 0.0% | 8.8% | — | $637M | $10M |
| 2021 | $1.9B | $131M | 0.0% | 10.6% | — | $990M | $387M |
| 2020 | $1.7B | -$796M | 0.0% | 5.7% | — | $1.7B | $1.1B |
| 2019 | $1.8B | -$1.5B | 0.0% | 9.7% | — | $1.7B | $108M |
| 2018 | $1.7B | $269M | 0.0% | 14.4% | — | $2.0B | $41M |
| 2017 | $3.3B | $320M | 0.0% | 14.0% | — | $1.8B | $40M |
| 2016 | $3.2B | $325M | 0.0% | 18.0% | — | $1.7B | $56M |
| 2015 | — | $336M | — | — | — | $1.3B | $52M |
| 2014 | — | $317M | — | — | — | $567M | $48M |
| 2013 | — | $281M | — | — | — | $27M | $31M |
| 2012 | — | $241M | — | — | — | — | $21M |
| 2011 | — | $218M | — | — | — | — | $19M |
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $476M | $30M | 0.0% | 8.7% | — | — | $206M |
| Dec '25 | $494M | $34M | 0.0% | 9.9% | — | — | $375M |
| Sep '25 | $493M | $72M | 0.0% | 13.8% | — | — | $340M |
| Jun '25 | $469M | $39M | 0.0% | 12.8% | — | — | $225M |
| Mar '25 | $458M | $21M | 0.0% | 7.0% | — | — | $99M |
| Dec '24 | $502M | $30M | 0.0% | 7.8% | — | $611M | $230M |
| Sep '24 | $511M | $19M | 0.0% | 6.6% | — | — | $104M |
| Jun '24 | $504M | -$153M | 0.0% | -31.3% | — | — | $19M |
| Mar '24 | $495M | $4M | 0.0% | 3.2% | — | — | $8M |
| Dec '23 | $496M | -$124M | 0.0% | -22.5% | — | $622M | $73M |
| Sep '23 | $507M | $21M | 0.0% | 7.9% | — | — | $21M |
| Jun '23 | $501M | $28M | 0.0% | 9.7% | — | — | $6M |
| Mar '23 | $491M | $14M | 0.0% | 6.1% | — | — | $6M |
| Dec '22 | $514M | $30M | 0.0% | 7.0% | — | $637M | $10M |
| Sep '22 | $490M | $31M | 0.0% | 9.7% | — | — | $9M |
| Jun '22 | $486M | $27M | 0.0% | 10.3% | — | — | $14M |
| Mar '22 | $482M | -$21M | 0.0% | 8.1% | — | — | $7M |
| Dec '21 | $499M | $48M | 0.0% | 13.6% | — | $990M | $387M |
| Sep '21 | $493M | $31M | 0.0% | 11.9% | — | — | $358M |
| Jun '21 | $473M | $35M | 0.0% | 10.6% | — | — | $338M |
How the market has priced MD against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 5 years, Pediatrix Medical Group, Inc.'s revenue has grown 2.0% per year. These are computed facts, not advice.
As of FY2025, Pediatrix Medical Group, Inc. reported — of total debt against $375M of cash; operating income covered interest expense 5.8×.
In FY2025, gross margin was —, operating margin 10.9%, and net margin 8.6%.
As of Jun '26, Pediatrix Medical Group, Inc. traded at a price-to-earnings ratio of about 12.0× (market cap ÷ latest annual net income). The valuation charts above show how its P/E, P/S have moved with the share price. These are computed facts, not advice.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.